BACKGROUND AIMS: The potential protective effects of mesenchymal stromal cells (MSCs) on some kidney diseases has been reported. However, the effect of MSCs on doxorubicin-induced nephropathy is still poorly understood. METHODS: Rats with doxorubicin-induced kidney injuries were treated with human cord-derived MSCs. Human MSCs were first labeled with 5-bromo-2'-deoxyuridine to track their homing in kidneys after infusion. RESULTS: Alleviation of proteinuria, decreased serum albumin, alleviation of lipid disorders and histologic alterations were found in rats 4 weeks after treatment with MSCs, particularly in rats that were given repeat doses. Decreases in serum levels of interleukin-6, tumor necrosis factor-α and prostaglandin E2 and decreases in messenger RNA levels of kidney tissue cylooxygenase-2 and EP4 were found in MSC-treated rats. MSC-treated rats also displayed an increase in serum interleukin-10 levels. CONCLUSIONS: These results indicate that MSCs ameliorate doxorubicin-induced kidney injuries and inflammation, suggesting a potential clinical treatment for inflammatory kidney diseases.
BACKGROUND AIMS: The potential protective effects of mesenchymal stromal cells (MSCs) on some kidney diseases has been reported. However, the effect of MSCs on doxorubicin-induced nephropathy is still poorly understood. METHODS:Rats with doxorubicin-induced kidney injuries were treated with human cord-derived MSCs. Human MSCs were first labeled with 5-bromo-2'-deoxyuridine to track their homing in kidneys after infusion. RESULTS: Alleviation of proteinuria, decreased serum albumin, alleviation of lipid disorders and histologic alterations were found in rats 4 weeks after treatment with MSCs, particularly in rats that were given repeat doses. Decreases in serum levels of interleukin-6, tumor necrosis factor-α and prostaglandin E2 and decreases in messenger RNA levels of kidney tissue cylooxygenase-2 and EP4 were found in MSC-treated rats. MSC-treated rats also displayed an increase in serum interleukin-10 levels. CONCLUSIONS: These results indicate that MSCs ameliorate doxorubicin-induced kidney injuries and inflammation, suggesting a potential clinical treatment for inflammatory kidney diseases.
Authors: Wagner de Fátima Pereira; Gustavo Eustáquio A Brito-Melo; Cayo Antônio Soares de Almeida; Lázaro Lopes Moreira; Cleiton Willian Cordeiro; Thiago Guimarães Rosa Carvalho; Elvis Cueva Mateo; Ana Cristina Simões E Silva Journal: Inflamm Res Date: 2015-03-19 Impact factor: 4.575
Authors: Diana A Papazova; Nynke R Oosterhuis; Hendrik Gremmels; Arianne van Koppen; Jaap A Joles; Marianne C Verhaar Journal: Dis Model Mech Date: 2015-01-29 Impact factor: 5.758
Authors: Csaba Imre Szalay; Katalin Erdélyi; Gábor Kökény; Enikő Lajtár; Mária Godó; Csaba Révész; Tamás Kaucsár; Norbert Kiss; Márta Sárközy; Tamás Csont; Tibor Krenács; Gábor Szénási; Pál Pacher; Péter Hamar Journal: PLoS One Date: 2015-06-18 Impact factor: 3.240